Quince Therapeutics, Inc.

NasdaqGS:QNCX Stock Report

Market Cap: US$82.7m

Quince Therapeutics Management

Management criteria checks 2/4

Quince Therapeutics' CEO is Dirk Thye, appointed in May 2022, has a tenure of 2.67 years. total yearly compensation is $1.33M, comprised of 41.3% salary and 58.7% bonuses, including company stock and options. directly owns 1.92% of the company’s shares, worth $1.59M. The average tenure of the management team and the board of directors is 1.7 years and 5.8 years respectively.

Key information

Dirk Thye

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage41.3%
CEO tenure2.7yrs
CEO ownership1.9%
Management average tenure1.7yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Aug 20

Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation

Nov 21
Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation

Cortexyme to change name and ticker symbol next month

Jul 27

Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment

Mar 01

Cortexyme: Drug Candidate COR588 May Offer Some Hope To Investors

Dec 15

We're Keeping An Eye On Cortexyme's (NASDAQ:CRTX) Cash Burn Rate

Dec 15
We're Keeping An Eye On Cortexyme's (NASDAQ:CRTX) Cash Burn Rate

Cortexyme: A Challenging Path Forward

Nov 17

Cortexyme: Positive Lessons To Be Learned From Disappointing Results

Nov 01

Cortexyme And The Gingipain Hypothesis Of Alzheimer's Disease

Oct 11

Cortexyme: Alzheimer's Readout In November A Binary Event

Sep 12

We Think Cortexyme (NASDAQ:CRTX) Can Afford To Drive Business Growth

Aug 23
We Think Cortexyme (NASDAQ:CRTX) Can Afford To Drive Business Growth

CEO Compensation Analysis

How has Dirk Thye's remuneration changed compared to Quince Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$53m

Jun 30 2024n/an/a

-US$53m

Mar 31 2024n/an/a

-US$30m

Dec 31 2023US$1mUS$550k

-US$31m

Sep 30 2023n/an/a

-US$28m

Jun 30 2023n/an/a

-US$31m

Mar 31 2023n/an/a

-US$42m

Dec 31 2022US$5mUS$317k

-US$52m

Compensation vs Market: Dirk's total compensation ($USD1.33M) is above average for companies of similar size in the US market ($USD645.47K).

Compensation vs Earnings: Dirk's compensation has been consistent with company performance over the past year.

CEO

Dirk Thye (54 yo)

2.7yrs

Tenure

US$1,330,500

Compensation

Dr. Dirk Thye, M.D., served as Chief Executive Officer, President and Director at Novosteo Inc. He has been Director at Kainomyx, Inc. Dr. Thye serves as Chief Medical Officer of Quince Therapeutics, Inc....

Leadership Team

NamePositionTenureCompensationOwnership
Dirk Thye
CEO, Chief Medical Officer & Director2.7yrsUS$1.33m1.92%
$ 1.6m
Charles Ryan
President1.3yrsUS$1.11m0.28%
$ 230.2k
Brendan Hannah
Chief Business Officer1.8yrsUS$847.50k0.67%
$ 557.5k
Giovanni Mambrini
Chief Technology Officer1.3yrsno datano data
Guenter Janhofer
Chief Scientific Officer1.3yrsno data0.034%
$ 28.2k
Stacy Roughan
Vice President of Corporate Communications & Investor Relations4yrsno datano data
Mary Sillivos
Vice President of Human Resources5yrsno datano data
Stewart Low
Head of Discovery2.7yrsno datano data
Thomas Sabia
Chief Commercial Officer1.3yrsno datano data
Pamela Williamson
Head of Regulatory Affairs1.5yrsno datano data

1.7yrs

Average Tenure

54yo

Average Age

Experienced Management: QNCX's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Dirk Thye
CEO, Chief Medical Officer & Director2.7yrsUS$1.33m1.92%
$ 1.6m
Una Ryan
Lead Independent Director6yrsUS$98.56k0.0065%
$ 5.4k
Ilan Zipkin
Member of Scientific Advisory Boardno dataUS$44.84kno data
Jeffrey Cummings
Member of Clinical Advisory Board5.6yrsno datano data
Martin Farlow
Member of Clinical Advisory Boardno datano datano data
David Lamond
Independent Chairman of the board9.1yrsUS$106.06k9.96%
$ 8.2m
Christopher Senner
Independent Director5.8yrsUS$87.56k0%
$ 0
Margaret McLoughlin
Independent Director9.1yrsUS$82.06k0.018%
$ 15.0k
Mark Brody
Member of Clinical Advisory Boardno datano datano data
David Munoz
Member of Clinical Advisory Boardno datano datano data
Mark Ryder
Member of Clinical Advisory Boardno datano datano data
Mauro Magnani
Chairman of Scientific Advisory Boardless than a yearno datano data

5.8yrs

Average Tenure

58.5yo

Average Age

Experienced Board: QNCX's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 21:29
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Quince Therapeutics, Inc. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Kumaraguru RajaBrookline Capital Markets
Sumant Satchidanand KulkarniCanaccord Genuity